Sign in
Knowstox

Fundamentals snapshot

OPKO Health, Inc.

OPK · NMS · Healthcare · Diagnostics & Research

Current price

$1.53

52-week range

$0.98 - $1.77

Market cap

$1.14B

One-glance verdict

Overvalued

$-0.02 our estimate vs market $1.53

Wall Street consensus: $4.15 (-27,027.1% lower than our fair-value estimate)

Balance sheet

Distressed

-1.23x Concerning

Net debt $97.32M. Interest coverage shows how many times profit covers the interest bill.

What this company does

OPKO Health, Inc.

OPKO Health develops and sells medicines and provides diagnostic testing services. Their main money comes from selling these medicines, like Rayaldee for a specific vitamin deficiency, and from their BioReference diagnostic labs that run various health tests for doctors. This matters because it shows they are trying to make money from both new drug development and established healthcare services.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Free cash flow by quarter (oldest to newest)
FY2024 Q3 $-85.02M FY2024 Q4 $-49.82M FY2025 Q1 $-37.75M FY2025 Q2 $-86.70M FY2025 Q3 $-37.78M FY2025 Q4 $-28.59M FY2026 Q1 $-21.14M FY2026 Q2 $-46.50M
Revenue $163.58M
Net income $-8.42M
Diluted EPS -0.01
Operating cash flow $-43.50M
Free cash flow $-46.50M
Revenue $124.20M
Net income $-54.85M
Diluted EPS -0.07
Operating cash flow $-19.31M
Free cash flow $-21.14M
Revenue $148.45M
Net income $-31.26M
Diluted EPS -0.04
Operating cash flow $-25.92M
Free cash flow $-28.59M
Revenue $151.67M
Net income $21.63M
Diluted EPS 0.03
Operating cash flow $-34.65M
Free cash flow $-37.78M
Revenue $156.81M
Net income $-148.44M
Diluted EPS -0.19
Operating cash flow $-83.42M
Free cash flow $-86.70M
Revenue $149.95M
Net income $-67.61M
Diluted EPS -0.10
Operating cash flow $-34.55M
Free cash flow $-37.75M
Revenue $183.64M
Net income $14.03M
Diluted EPS 0.01
Operating cash flow $-44.41M
Free cash flow $-49.82M
Revenue $173.63M
Net income $24.89M
Diluted EPS 0.03
Operating cash flow $-77.08M
Free cash flow $-85.02M

Is it cheap or expensive?

Fair value $-0.02 vs current price $1.53

Wall Street consensus is the average analyst price target: $4.15 (-27,027.1% lower than our fair-value estimate).

Our most-likely fair value is $-0.02 a share — about 101.0% below today's price of $1.53, so the stock currently looks expensive (overvalued).

overvalued

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Base

Growth 3.0% · Discount 10.4% · Terminal 3.0%

$-0.02

Bear

Growth 3.0% · Discount 10.4% · Terminal 3.0%

$-0.02

Bull

Growth 6.0% · Discount 10.4% · Terminal 3.0%

$0.01

Is it drowning in debt?

Distressed

Net debt $97.3M. Interest coverage -1.2x.

Net debt $97.32M
Interest coverage -1.23x

OPKO Health, Inc. is healthier than 0 of 1 peers on balance-sheet leverage.

Distressed
Worse cushion Baseline Better cushion
OPK BASELINE OPKO Health, Inc.

Total debt $398.08M Interest coverage -1.23x This is the baseline the peer rows are being compared against.

-1.23x

What you should know

The case for and against OPK

1 Reward 1 Risk

Rewards

  • Free cash flow was positive in 3/10 years.

Risks

  • Return on equity was -5.9% last year — the company lost money on shareholders' equity.

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
—
Forward P/E
-4.46x
P/B
0.96x
P/S
1.94x
EV/EBITDA
-15.85x
PEG ratio
93.65x

Profitability

How much profit each dollar creates

Gross margin
19.5%
Operating margin
-15.3%
Net margin
-12.4%
ROE
-5.9%
ROA
-5.5%

Health

Liquidity and balance-sheet strength

Debt / equity
0.34x
Current ratio
3.35x
Quick ratio
2.65x
Total debt
$398.08M
Total cash
$300.76M

Growth

How the business has been compounding

Revenue TTM
$587.90M
Revenue 5Y CAGR
-23.5%
EPS TTM
-0.09
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-123.38M
Free CF TTM
$-190.82M
FCF margin
-32.5%

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—